Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk episode artwork

EPISODE · Jul 24, 2024 · 38 MIN

Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk

from In Good Company with Nicolai Tangen

Rerun:“I'm very concerned that European citizens will have lack of access or much lower access to some of the new medicines” says CEO of Novo Nordisk. He also share some interesting perspectives about the importance of purpose and their new weight loss drug.The production team on this episode were PLAN-B’s Niklas Figenschau Johansen and Nikolai Ovenberg. Background research was done by Sigurd Brekke with input from portfolio manager Gemma Game.Watch the episode on YouTube: Norges Bank Investment Management - YouTubeWant to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedInFollow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedInFollow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Jul 24, 2024

Embed this episode

NOW PLAYING

Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk

0:00 38:48

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of In Good Company with Nicolai Tangen?

This episode is 38 minutes long.

When was this In Good Company with Nicolai Tangen episode published?

This episode was published on July 24, 2024.

Can I download this In Good Company with Nicolai Tangen episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!